Hubei Biocause Pharmaceutical Co Ltd
SZSE:000627
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.64
5.18
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Balance Sheet
Balance Sheet Decomposition
Hubei Biocause Pharmaceutical Co Ltd
| Cash & Short-Term Investments | 11.8B |
| Insurance Receivable | 1.6B |
| PP&E | 1.5B |
| Long-Term Investments | 209.3B |
| Other Assets | 54.2B |
| Insurance Policy Liabilities | 235.8B |
| Long Term Debt | 5.6B |
| Other Liabilities | 16.5B |
Balance Sheet
Hubei Biocause Pharmaceutical Co Ltd
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
59
|
62
|
10 953
|
11 152
|
18 317
|
13 680
|
27 029
|
25 650
|
30 665
|
28 577
|
|
| Cash |
0
|
0
|
247
|
0
|
0
|
0
|
0
|
23 250
|
26 309
|
28 154
|
|
| Cash Equivalents |
59
|
62
|
10 706
|
11 152
|
18 317
|
13 680
|
27 029
|
2 399
|
4 356
|
424
|
|
| Total Receivables |
335
|
70
|
6 706
|
7 414
|
7 717
|
1 348
|
1 957
|
2 984
|
3 863
|
4 354
|
|
| Insurance Receivable |
0
|
0
|
251
|
201
|
261
|
322
|
1 545
|
772
|
936
|
1 171
|
|
| Total Current Assets |
394
|
131
|
17 659
|
18 566
|
26 035
|
15 027
|
28 986
|
28 634
|
34 528
|
32 931
|
|
| PP&E Net |
463
|
335
|
587
|
699
|
853
|
585
|
605
|
830
|
844
|
1 291
|
|
| PP&E Gross |
463
|
335
|
587
|
699
|
853
|
585
|
605
|
830
|
844
|
1 291
|
|
| Accumulated Depreciation |
404
|
475
|
588
|
646
|
661
|
51
|
68
|
138
|
216
|
260
|
|
| Intangible Assets |
504
|
490
|
549
|
520
|
213
|
109
|
190
|
270
|
299
|
283
|
|
| Goodwill |
0
|
0
|
6 186
|
6 186
|
6 186
|
6 186
|
6 192
|
6 192
|
6 192
|
6 193
|
|
| Note Receivable |
31
|
292
|
20 317
|
17 884
|
38 759
|
24 434
|
35 676
|
38 257
|
37 987
|
42 304
|
|
| Long-Term Investments |
717
|
1 161
|
72 327
|
96 360
|
105 946
|
158 610
|
166 208
|
188 948
|
207 812
|
217 763
|
|
| Other Assets |
0
|
0
|
6 186
|
6 186
|
6 186
|
6 186
|
6 192
|
6 192
|
6 192
|
6 193
|
|
| Total Assets |
2 108
N/A
|
2 409
+14%
|
117 877
+4 793%
|
140 417
+19%
|
178 254
+27%
|
205 274
+15%
|
239 403
+17%
|
263 904
+10%
|
288 599
+9%
|
301 936
+5%
|
|
| Liabilities | |||||||||||
| Insurance Policy Liabilities |
0
|
0
|
93 801
|
110 767
|
144 687
|
168 392
|
198 891
|
216 419
|
243 408
|
256 932
|
|
| Accounts Payable |
148
|
126
|
1 708
|
1 762
|
6 509
|
1 479
|
1 643
|
2 478
|
2 350
|
2 817
|
|
| Short-Term Debt |
449
|
319
|
424
|
287
|
29
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
5
|
7
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
8
|
10
|
4
|
|
| Total Current Liabilities |
597
|
445
|
2 132
|
2 053
|
6 544
|
1 479
|
1 644
|
2 486
|
2 360
|
2 821
|
|
| Long-Term Debt |
0
|
42
|
360
|
41
|
111
|
0
|
2 760
|
6 243
|
6 880
|
7 171
|
|
| Deferred Income Tax |
22
|
139
|
1 186
|
850
|
897
|
1 049
|
1 519
|
1 281
|
1 348
|
1 378
|
|
| Minority Interest |
41
|
44
|
6 596
|
7 368
|
7 022
|
13 130
|
13 453
|
14 921
|
13 191
|
13 044
|
|
| Total Liabilities |
659
N/A
|
670
+2%
|
104 075
+15 434%
|
121 080
+16%
|
159 262
+32%
|
184 051
+16%
|
218 268
+19%
|
241 351
+11%
|
267 187
+11%
|
281 346
+5%
|
|
| Equity | |||||||||||
| Common Stock |
1 354
|
1 354
|
4 259
|
4 941
|
4 941
|
4 941
|
4 941
|
4 941
|
4 941
|
4 941
|
|
| Retained Earnings |
65
|
313
|
2 050
|
3 270
|
4 399
|
6 026
|
6 112
|
6 533
|
6 783
|
5 588
|
|
| Additional Paid In Capital |
30
|
30
|
6 917
|
11 071
|
11 098
|
11 095
|
11 095
|
11 094
|
11 094
|
11 041
|
|
| Unrealized Security Profit/Loss |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
56
|
1 471
|
1 072
|
|
| Other Equity |
0
|
43
|
575
|
56
|
1 445
|
839
|
1 013
|
41
|
66
|
93
|
|
| Total Equity |
1 449
N/A
|
1 740
+20%
|
13 802
+693%
|
19 337
+40%
|
18 992
-2%
|
21 223
+12%
|
21 135
0%
|
22 553
+7%
|
21 412
-5%
|
20 590
-4%
|
|
| Total Liabilities & Equity |
2 108
N/A
|
2 409
+14%
|
117 877
+4 793%
|
140 417
+19%
|
178 254
+27%
|
205 274
+15%
|
239 403
+17%
|
263 904
+10%
|
288 599
+9%
|
301 936
+5%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
1 354
|
1 354
|
4 259
|
4 941
|
4 941
|
4 941
|
4 941
|
4 941
|
4 941
|
4 941
|
|
You don't have any saved screeners yet
